LinkedIn Profile

Access Capricor Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:capr 2387515 Apr 21st, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 110.00 Open Apr 20th, 2024 11:06PM Apr 20th, 2024 11:06PM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 20th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 110.00 Open Apr 19th, 2024 11:06PM Apr 20th, 2024 04:42PM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 19th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 109.00 Open Apr 18th, 2024 11:13PM Apr 18th, 2024 11:13PM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 18th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 109.00 Open Apr 17th, 2024 11:12PM Apr 18th, 2024 06:02PM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 17th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 109.00 Open Apr 16th, 2024 11:01PM Apr 17th, 2024 02:26PM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 16th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 109.00 Open Apr 15th, 2024 10:55PM Apr 16th, 2024 10:42AM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 15th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 109.00 Open Apr 14th, 2024 10:55PM Apr 15th, 2024 04:23PM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 14th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 108.00 Open Apr 13th, 2024 10:44PM Apr 14th, 2024 10:42AM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 13th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 108.00 Open Apr 12th, 2024 10:35PM Apr 13th, 2024 11:10AM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics
nasdaq:capr 2387515 Apr 12th, 2024 12:00AM Capricor Therapeutics, Inc. 9.3K 108.00 Open Apr 11th, 2024 10:39PM Apr 12th, 2024 08:05AM Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. Open Biotechnology, Duchenne muscular dystrophy, RNA Therapeutics, Extracellular Vesicles , Exosomes, Cell Therapy , Rare Diseases, and Infectious Diseases Open 10865 Road To The Cure San Diego CA - California US 92121 Capricor Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.